
ICICI Securities has issued a buy rating on Thyrocare Technologies with a revised target price of ₹620, down from the earlier target of ₹650. As per the latest research report dated October 30, 2026, the brokerage maintains its bullish stance despite cutting FY27/28E EPS estimates by 1-6% to factor in the divestment of its imaging arm. The stock currently trades at valuations of 40.9x FY27E and 34x FY28E earnings, with EV/EBITDA multiples of 24.1x FY27E and 20.3x FY28E. The revised target price implies 40.9x FY28E earnings and a 24.7x FY28E EV/EBITDA multiple.
Healthcare diagnostics firm Thyrocare Technologies reported a 68.17% year-on-year decline in net profit to ₹15.22 crore for the September quarter of FY27, compared with ₹48 crore in the year-ago period. According to reports from CNBC TV18, the decline came despite positive operational metrics, as the company recognised an exceptional impairment charge of ₹44.98 crore relating to its investment in Nuclear Healthcare Limited (NHL). Revenue rose 25.1% year-on-year to ₹271 crore from ₹217 crore, while earnings before interest, tax, depreciation and amortisation (EBITDA) increased 25.1% to ₹89 crore from ₹71 crore. The EBITDA margin remained flat at 33% year-on-year. However, Thyrocare also reported that PAT before exceptional items surged 25.7% YoY to ₹60.2 crore, underscoring the company's focus on profitable growth.
Thyrocare demonstrated strong network expansion during Q2FY27, adding 1,181 franchisees to its network, taking the total count to 12,911. According to ICICI Securities research, the franchisee segment reported 27% growth while partnership revenue increased 27.9% year-on-year. The company processed 61.6 million tests during the quarter, registering year-on-year growth of 27.4%. Quality metrics showed improvement with customer complaints declining 24% year-on-year to 2.9 per million, while the average turnaround time (ATAT) stood at 3.49 hours from sample receipt. The company maintained Six Sigma-level performance during the quarter.
The company is proceeding with the divestment of its imaging arm, Nuclear Healthcare Ltd., to Trovera for ₹1,414 million by end-November 2026. As reported by ICICI Securities, management has raised its FY27 revenue growth guidance to >20% (15-17% earlier) with EBITDA margins between 31-31.5%. The brokerage expects network addition of 1,500-2,000 franchisees annually and rising contribution from specialised tests, which could help the pathology segment sustain its growth pace. The company's specialty diagnostics portfolio continues to expand, with emphasis on allergy testing, genomics, and the launch of a pregnancy test kit available at more than 10,000 chemist outlets.
Rahul Guha, managing director and CEO of Thyrocare Technologies, said the company delivered a strong performance during the quarter, supported by operational efficiency, network expansion and value-driven diagnostics. According to reports from CNBC TV18, Guha highlighted the expansion of the specialty portfolio through allergy testing and the entry into genomics, alongside efforts to expand the franchise and partner network in underserved regions. Guha also revealed that the company was preparing to enter the point-of-care devices segment with a differentiated offering, adding that he hoped to see its presence across all major chemist outlets in the near future. Thyrocare Technologies shares rose 4.55% to close at ₹517 on October 29, up ₹22.50, ahead of the company's Q2 earnings announcement.